Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

The Øresund Bridge is currently closed to traffic heading towards Denmark at the request of the police, as confirmed on X. The closure follows a minor traffic accident caused by a driver who refused ...

At the close in Copenhagen,... The FDA's Blood Products Advisory Committee will convene tomorrow to review and discuss Novo Nordisk (CO:NOVOb)'s (NVO -0.5%) Biologics License Application (BLA ...

In 2024, the Association for Eating Disorders and Self-Harm reported a 22% increase in support requests, with a record 6,754 conversations held across phone, chat, SMS, and in-person consultations.

COPENHAGEN (Reuters) - Drugmaker Novo Nordisk (CO:NOVOb) said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could... Investing.com ...

Renewed U.S. interest has given a boost to Greenland's independence movement and strengthened its position in future ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...